COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
Bausch Health's Solta Medical to feature Thermage FLX, Clear + Brilliant, and Fraxel FTX on The Balancing Act. Innovative treatments for youthful appearance showcased on Lifetime TV -
-
COMMUNIQUÉ DE PRESSE
Wellgistics Health (NASDAQ:WGRX) and TheracosBio Partner to Expand Nationwide, PBM-Free Access to Brenzavvy(R), an FDA-Approved Diabetes Therapy, Through 6,500+ Pharmacies
Wellgistics Health partners with TheracosBio to improve affordability and access to diabetes medication Brenzavvy in the U.S. healthcare system through their maker-to-taker platform and network of 6,500+ pharmacies -
COMMUNIQUÉ DE PRESSE
United Labels reports on the first half of the year and expects positive development for 2025 as a whole
United Labels AG reports on the first half of 2025, reflecting a decline in revenue due to order shifts but anticipates growth for the full year. The company's online business saw a 6% sales increase -
COMMUNIQUÉ DE PRESSE
VVV Sports Limited: Interim Results for the six months ended 30 June 2025
VVV Sports Limited announces unaudited interim results for the six months to 30 June 2025. Focus shifts from mineral exploration to sports and media investment sector. Completed a capital raise of £1,000,000 to support new direction -
COMMUNIQUÉ DE PRESSE
Atlas Salt Announces Updated Feasibility Study with Enhanced Results for the Great Atlantic Salt Project; $920M Post-Tax NPV8 and 21.3% Post-Tax IRR
Atlas Salt Inc. announces results of Updated Feasibility Study for Great Atlantic Salt Project, projecting strong financial outlook and operational efficiency -
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
MIRA Pharmaceuticals completes acquisition of SKNY Pharmaceuticals, strengthening financial position. SKNY-1 for obesity and smoking cessation, Ketamir-2 for neuropathic pain, and MIRA-55 for inflammatory pain -
COMMUNIQUÉ DE PRESSE
E-Cite Motors Executes Stock Lockup Agreement Eliminating 90% of Potential Conversions, Strengthening Capital Structure and Protecting Shareholders
E-Cite Motors' largest investor commits to one-year lockup, safeguarding shareholder value and ensuring long-term growth. Regulatory advantage propels company ahead of traditional OEMs -
